title: Laboratory and clinical characteristics of Staphylococcus lugdunensis prosthetic joint infections.
abstract: Staphylococcus lugdunensis is a coagulase-negative staphylococcus that has several similarities to Staphylococcus aureus. S. lugdunensis is increasingly being recognized as a cause of prosthetic joint infection (PJI). The goal of the present retrospective cohort study was to determine the laboratory and clinical characteristics of S. lugdunensis PJIs seen at the Mayo Clinic in Rochester, MN, between 1 January 1998 and 31 December 2007. Kaplan-Meier survival methods and Wilcoxon sum-rank analysis were used to determine the cumulative incidence of treatment success and assess subset comparisons. There were 28 episodes of S. lugdunensis PJIs in 22 patients; half of those patients were females. Twenty-five episodes (89%) involved the prosthetic knee, while 3 (11%) involved the hip. Nine patients (32%) had an underlying urogenital abnormality. Among the 28 isolates in this study tested by agar dilution, 24 of 28 (86%) were oxacillin susceptible. Twenty of the 21 tested isolates (95%) lacked mecA, and 6 (27%) of the 22 isolates tested produced beta-lactamase. The median durations of parenteral beta-lactam therapy and vancomycin therapy were 38 days (range, 23 to 42 days) and 39 days (range, 12 to 60 days), respectively. The cumulative incidences of freedom from treatment failure (standard deviations) at 2 years were 92% (+/-7%) and 76% (+/-12%) for episodes treated with a parenteral beta-lactam and vancomycin, respectively (P=0.015). S. lugdunensis is increasingly being recognized as a cause of PJIs. The majority of the isolates lacked mecA. Episodes treated with a parenteral beta-lactam antibiotic appear to have a more favorable outcome than those treated with parenteral vancomycin.
authors.affiliation: Department of Internal Medicine, Division of Infectious Disease, Section of Orthopedic Infectious Diseases, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA. shah.neel@mayo.edu
authors.forename: Neel B
authors.initials: NB
authors.lastname: Shah
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Osmon
authors.forename: Hind
authors.initials: H
authors.lastname: Fadel
authors.forename: Robin
authors.initials: R
authors.lastname: Patel
authors.forename: Peggy C
authors.initials: PC
authors.lastname: Kohner
authors.forename: James M
authors.initials: JM
authors.lastname: Steckelberg
authors.forename: Tad
authors.initials: T
authors.lastname: Mabry
authors.forename: Elie F
authors.initials: EF
authors.lastname: Berbari
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology*; D015331:Cohort Studies; D005260:Female; D005798:Genes, Bacterial; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008910:Minnesota / Q000453:epidemiology; D015995:Prevalence; D016459:Prosthesis-Related Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology*; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000473:pathology*; D013210:Staphylococcus / Q000302:isolation & purification*; D016896:Treatment Outcome; D014640:Vancomycin / Q000627:therapeutic use; D001618:beta-Lactamases / Q000096:biosynthesis; D047090:beta-Lactams / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D014640:Vancomycin; D001618:beta-Lactamases